

Predicting Antibody Responses to Type V GBS-TT Conjugate Vaccine Using Computational Modelling



25th International Conference on Computational Science - 2025
Singapore

Matheus Ribeiro, Bárbara Quintela, **Ruy Freitas Reis**,
Rodrigo dos Santos and Marcelo Lobosco

July 7–9th, 2025

Pós-Graduação em Modelagem Computacional
Departamento de Ciência da Computação
Universidade Federal de Juiz de Fora

1. Introduction
2. Background
3. Methods
4. Results and Discussion
5. Conclusion and Future Work

Introduction

- Group B Streptococcus (GBS) is a leading cause of neonatal mortality and morbidity.
 - 410,000 cases worldwide, leading to 147,000 stillbirths and infant deaths
- It can cause severe infections like sepsis, pneumonia, and meningitis in newborns.
- Current prevention relies on maternal screening and intrapartum antimicrobial prophylaxis (IAP).
- Maternal vaccination is a promising strategy, offering transplacental transfer of antibodies for protection.
- The Type V GBS-TT conjugate vaccine is a significant development.

- Computational models are valuable tools in vaccine research.
- They simulate disease dynamics, immune responses, and vaccine effects within a controlled virtual environment.
- Such models enable rapid exploration of scenarios, including variations in vaccine dosage and administration schedules.
- Ordinary differential equation (ODE) models offer a balance between interpretability and computational efficiency.
- In this study, we extend an established ODE model to evaluate the Type V GBS-TT conjugate vaccine.

Background

- GBS (*Streptococcus agalactiae*) is a common bacterium and a major cause of neonatal infections.
- The innate immune system acts as the first line of defense, involving cells such as neutrophils and macrophages.
- The adaptive immune system produces specific antibodies against GBS antigens, primarily targeting the polysaccharide capsule.
- Vaccines mimic natural infection to elicit memory immune responses without causing disease.
- The Type V GBS-TT conjugate vaccine uses capsular polysaccharides (CPS) conjugated with tetanus toxoid (TT) to enhance immunogenicity.

- A study by Baker *et al.*¹ evaluated the Type V GBS-TT conjugate vaccine at different dosages in healthy adults.
- The vaccine elicited a dose-dependent immune response, with higher doses inducing greater production of specific antibodies.

¹Baker *et al.*, Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. *Vaccine*, 25(1), pp. 55–63, Jan 2007.





Figure 1: Sum of IgG, IgM and IgA for the distinct vaccines. Cohort data from Baker *et al.*


Methods

- The model is a system of ordinary differential equations (ODEs), adapted from Bonin *et al.* ²
- It describes interactions among:
 - Vaccine particles (Vp),
 - Antigen-presenting cells (naive Ap, mature Apm),
 - Lymphocytes (Thn, The, Tkn, Tke, B, Bm, Ps, PI),
 - Antibodies (A).
- The model includes terms for vaccine elimination, cell maturation, activation, replication, differentiation, and decay.

²Bonin *et al.*, Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, revaccination and dose-response in adults, and studies with immunocompromised individuals. *BMC Bioinformatics*, 21(S17), Dec 2020.




$$\frac{d}{dt}V_p = - \frac{c_{v1}V_p}{c_{v2} + V_p} - k_{v1}V_pA - k_{v2}V_pT_E$$




Innate system action

$$\frac{d}{dt}V_p = -\frac{c_{v1}V_p}{c_{v2} + V_p} - \boxed{k_{v1}V_pA} - k_{v2}V_pT_E$$



Neutralization by antibodies

$$\frac{d}{dt}V_p = -\frac{c_{v1}V_p}{c_{v2} + V_p} - k_{v1}V_pA - \boxed{k_{v2}V_pT_E}$$



Elimination by T killer cells

- Cohort data were extracted from a phase 1 trial comparing the Type V GBS-TT conjugate vaccine (V-TT) with an unconjugated Type V capsular polysaccharide (V-CPS) vaccine.
- Healthy adults (aged 18–50 years) were assigned to four vaccine groups.
- Blood samples were collected at baseline and at 4, 8, 26, and 52 weeks post-vaccination.

- Type V CPS-specific antibodies (IgG, IgA, and IgM) were quantified using ELISA.
- Differential Evolution (DE) was employed to calibrate seven key model parameters.
- The objective function minimized the L_2 norm of the relative error between observed and simulated antibody levels.

Results and Discussion




Figure 2: Unconjugated CPS: 37 μg




Figure 3: V-TT: 38.5 μ g CPS/17.0 μ g TT




Figure 4: V-TT: 9.6 μ g CPS/4.3 μ g TT




Figure 5: V-TT: 2.4 μ g CPS/1.1 μ g TT

- The model accurately reproduced the dose-dependent antibody response observed in the clinical trial.
- Higher CPS doses elicited stronger and more sustained antibody levels.
- The highest V-TT dose ($38.5 \mu\text{g}$ CPS / $17.0 \mu\text{g}$ TT) showed near-perfect alignment with cohort data.
- Lower doses ($2.4 \mu\text{g}$ CPS / $1.1 \mu\text{g}$ TT) exhibited greater discrepancies, with simulated titers consistently falling below the geometric mean titer (GMT).
- These deviations suggest opportunities for model refinement.

- The DE algorithm successfully calibrated seven key parameters to fit the model to cohort data for both unconjugated CPS and conjugated V-TT vaccines.
- Significant differences were observed between the two vaccine formulations, reflecting distinct immunological mechanisms.
- For the V-TT vaccine, the antigen-presenting cell maturation rate (β_{ap}) was 93 times higher than for the unconjugated vaccine.
 - This supports the adjuvant effect of tetanus toxoid.

- The antibody-mediated vaccine clearance rate (k_{v1}) was approximately 1,700 times higher for the conjugated vaccine, suggesting more effective neutralization of vaccine particles.
- The short-lived plasmocyte decay rate (δ_{ps}) remained consistent across formulations.
- The antibody decay rate (δ_A) was slightly higher for the V-TT conjugate vaccine.

Conclusion and Future Work

- Developed a computational model to simulate the immune response to the Type V GBS-TT conjugate vaccine.
- Successfully reproduced clinical trial data across multiple dosage groups.
- Calibration using Differential Evolution provided mechanistic insights into dose-dependent efficacy.
- The conjugated V-TT vaccine elicited a more robust and sustained antibody response than the unconjugated CPS formulation.
- Enhanced APC maturation and accelerated antibody-mediated clearance emerged as key contributors to the superior immune response.

- Incorporate additional parameters into the calibration process to improve model precision.
- Explore uncertainty quantification to assess confidence in model predictions.
- Integrate patient-specific immune profiles to enable personalized dosing strategies, especially for high-risk populations.

Obrigado!
Thanks!

